Member Info for zebbo

30 vacancies worldwide, current staff count 102. Now that feels like a significant staffing ramp up post FDA.

Now why would they be scaling up to that extent??

That is the most important aspect IMO. We have effective cornered the market for the capture, harvest and analysis of circulating tumour cells. Moats dont get any better :-)

Wow, only just listened to the interview. Looks like the commercial floodgates are opening. AN certainly answered the commercial concerns that where swirling around (mainly by people who are not posting today:--). Rome was not built in a day but the business model is sound and the mote massive for any new entrant.
It only will only take a handful of customers/case studies for Angle to become the go to diag company for said cancer types. Lets just hope we scale before Abbott take us out....

She must have found the buy button, along with Emerald carrot. Same old MO

He should have raised funds before he opened his mouth. I expect a move back to 20p level near term, to much in the mix to see DDDD fail

Feels like this has now been way oversold. DDDD has a lot of inherent value that far outweighs the current mcap

We are very pleased with the increasing levels of interest from pharma companies in our CTC analysis services following FDA clearance of the Parsortix system and look forward to announcing further progress on the expansion of this important business area for ANGLE in due course."

When Abbott have a such a significant deficiency in such a key sector going forwards (liquid biopsy market) would they really, as a $183bn company want to stick to just being involved in one subsector of MBC testing and then be content with that, letting other companies dominate this field? Or would they want the whole company to get a powerful position within the wider liquid biopsy market, also enabling them to tie up and sell through companies like Exact Sciences etc. leveraging their investment beyond just expanding their current market.

As I say, this is all speculation, but it is in my view well founded speculation. Nothing would surprise me and Angle's directors are already loaded up to the hilt with options. In particular, if Abbott came in with an offer for Angle after FDA approval I would not at all be surprised. And in my view, this would have to be somewhere between £5-£10 to have any chance of success. And such a price is really just a drop in the ocean for Abbott. It would be petty change for them to do a deal.

Abbott is generating cash that it is sitting on. In 2019, cash was $3.8bn. In 2020, cash was $6.8bn. In 2021, cash was $9.8bn. They could buy Angle at a price many shareholders would be happy with, just from a fraction of the increase in their cash balance this year. No guarantees of course, but why would they not?
—-
POSTSCRIPT - this article speaks volumes...

hTTps://www.mddionline.com/covid-19/abbott-looking-ma-opportunities
- Abbott has somewhere north of $40 billion worth of capacity on the balance sheet
- When the Abbott CEO was asked if liquid biopsy and cancer screening diagnostics might be of interest, he said "Devices and diagnostics, I will say, are the areas that we're looking at more carefully," Ford said. "... The areas that you referenced are areas that we would be interested in looking at."
[Now name me an FDA approved device that is involved in liquid biopsy and cancer other than Parsortix...]
- "He also indicated that we're most likely to see Abbott go after tuck-in acquisitions and perhaps even some medium-sized deals, so long as the right opportunities present themselves".

For those who dont access ADVFN,
(originally on Telegram - numbers updated) as (1) the likelihood of a takeover will increase at these levels, and also given the comment by Newland in the presentation about the most advanced discussions being with Abbott...
—-
Remember that Abbott Laboratories is not your normal pharma. It specialises in in "diagnostics, medical devices, nutrition and branded generic pharmaceuticals".

Despite being valued at $183bn, and despite specialising in medical diagnostics and devices, you might be surprised to know that Abbott Laboratories have no real liquid biopsy foothold.

If you google "liquid biopsy" and "Abbott Laboratories", the first two things that come up on the google search are the collaboration between Angle and Abbott, even without including Angle's name in the search hTTps://www.google.com/search?q=%22abbott+laboratories%22+%22liquid+biopsy%22&oq=%22&aqs=edge.0.69i59j69i57j69i59l4.1309j0j1&sourceid=chrome&ie=UTF-8

Next, if you look at Abbott's annual report, the words "liquid biopsy" "ctdna" AND "ctc" appear nowhere.

In short, when it comes to this critical current and forward looking area of medical diagnostics and devices (liquid biopsies) Abbott is in the dark ages. In this important sector (and I do not suggest anything wider than that) Abbott are at risk of being IBM in the days of Microsoft, Apple, Google, Facebook and Nvidia. They are at risk of having missed the boat in one of the largest new areas of medical science.

So it is no wonder that Abbott want to be involved in the liquid biopsy space and they have already collaborated with Angle on the MBC trial that is the bedrock of the FDA application. We are also being told by Berenberg and other established sources that FDA approval should kick off an "Abbott breast cancer partnership", "which should translate into a prompt monetary benefit".

We also know from the Finncap report that "Although there is no commercial agreement with Abbott as yet, testing of CTCs for HER-2 could provide Abbott with a repeat test for HER-2 giving a 4x increase in use of their PathVysion test; creating a market worth c.$2bn." (note this would be an annual market)

Investing in Angle by way of a partnership giving exclusivity in just one nice sector within a sector (HER-2 / FISH testing in MBC), could therefore give Abbott a very, very healthy return on their investment. But why would they want to stop there, in such a niche area?

An Abbott takeover offer struck shortly after FDA approval (which would give them the corporate green light to spend money) is in my view a real and distinct possibility. Abbott will already have done large amounts of the DD required through the collaboration on MBC and they will now already have evidence of the wider commerciality of Parsortix as Angle are getting contracts in with repeat business including a Phase 3 trial, all before CLIA and FDA approval.

Always those that sold at a loss that have an axe to grind.

I know you all need to vent, but gets a bit.......yawn

I was kidding, but poor comparison to say the least

Sirious or Serious ...haha

expect news is incoming

Deepestblue your the best..hahaha

While people look at technicals, you need to bear in mind this is AIM and not some bot traded FTSE stock.
**Bottom line, tech is proven, they need to ramp up partners. Worst case we get taken out ;-)
Its the AIM game, some peeps will no doubt be starting to panic, especially if stock was bought in the 1.50 range. That said dont be surprised if we reach new highs within the next 12 months as partnerships build and sentiment changes

Deepestblue, you are the best ever...lol

https://www.evaluate.com/vantage/articles/news/policy-and-regulation-snippets/new-kind-liquid-biopsy

Table shows how competitive we are....

Parsortix instrument costs around £40,000 ($52,000), with the single-use cassettes needed to analyse samples going for around £100 – but this was in Europe, and for research rather than clinical use. How the system will be priced in the US is not yet clear, though Angle said that per test, Parsortix would be “substantially cheaper” than the average cost of a breast cancer tissue biopsy – $16,000 in the US

nice to see a strong bounce on volume. The "other" BB seems a lot more positive than LSE

That aside, the right news and we will jump another 50%. Based on the last few weeks we know this can move in both directions at pace. However the difference is that AGL is now on a very solid footing, with the FDA tick in the box

Swaptions had 3x by EO March, I would guess we may be at 5x if still holding ie ~$1B

If Bill tweeted he was going to wind the fund up, we would be £35+

Some people cannot look beyond the end of the week...lol
Our tech and positioning in the market makes this a no brainier 12-24 mths out